Arzu Yilmaztepe Oral

Arzu Yilmaztepe Oral

Auto-generated profile, based on publicly available information

Arzu Yilmaztepe Oral

BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AOArzu Yilmaztepe Oral
Arzu Yilmaztepe Oral
BCBuse Cevatemre
Buse Cevatemre
MSMehmet Sarimahmut
Mehmet Sarimahmut
CICeyda Icsel
Ceyda Icsel
VYVeysel Turan Yilmaz
Veysel Turan Yilmaz
EUEngin Ulukaya
Engin Ulukaya


23 October 2019 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Didem KarakasDidem Karakas
Didem Karakas
BCBuse Cevatemre
Buse Cevatemre
AOArzu Yilmaztepe Oral
Arzu Yilmaztepe Oral
VYVeysel Turan Yilmaz
Veysel Turan Yilmaz
EUEngin Ulukaya
Engin Ulukaya
Background: Prostate cancer is one of the most common cancer types and it is the sixth leading cause of cancer-related death in men worldwide. Even though novel treatment modalities have been developed, it still a lifethreatening disease. Therefore novel compounds are needed to improve the overall survival.Methods: In our study, it was aimed to evaluate the anti-cancer activity of newly synthesized Platinum (II) [Pt(II)] complex on DU145, LNCaP and PC-3 prostate cancer cell lines. The cytotoxic activity of Pt(II) complex was tested by SRB and ATP cell viability assays. To detect the mode of cell death; fluorescent staining, flow cytometry and western blot analyses were performed.Results: The Pt(II) complex treatment resulted in a decrease in cell viability and increasing levels of apoptotic markers (pyknotic nuclei, annexin-V, caspase 3/7 activity) and a decrease in mitochondrial membrane potential in a dose dependent manner. Among cell types, tested PC-3 cells were found to be more sensitive to Pt(II) complex, demonstrating elevation of DNA damage in this cell line. In addition, Pt(II) complex induced Endoplasmic Reticulum (ER) stress by triggering ROS generation. More importantly, pre-treatment with NAC alleviated Pt(II) complex-mediated ER stress and cell death in PC-3.Conclusion: These findings suggest an upstream role of ROS production in Pt(II) complex-induced ER stressmediated apoptotic cell death. Considering the ROS-mediated apoptosis inducing the effect of Pt(II) complex, it warrants further evaluation as a novel metal-containing anticancer drug candidate.

30 September 2025 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
GAGöksel Aydoğan
Göksel Aydoğan
VDVahide Aslıhan Durak
Vahide Aslıhan Durak
AAAyşe Armağan Aydoğan
Ayşe Armağan Aydoğan
YDYasemin Dinc
Yasemin Dinc
BABeliz Akçakoca
Beliz Akçakoca
AOArzu Yılmaztepe Oral
Arzu Yılmaztepe Oral
Aim: This study aimed to investigate the association between serum ischemia-modified albumin (IMA) levels, stroke severity, and functional outcomes in adult patients diagnosed with acute ischemic stroke (AIS) in the emergency department. Material and Methods: In this prospective observational study, 40 AIS patients and 20 age- and sex-matched healthy controls were enrolled. Serum IMA levels were measured at admission using a commercial ELISA kit. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes at 3 months were determined using the modified Rankin Scale (mRS), with scores ≥2 defined as poor functional outcome (PFO). Results: Median IMA levels were significantly higher in AIS patients than controls. Elevated IMA was independently associated with AIS (adjusted OR: 1.18, 95% CI: 1.03–1.35, p = 0.015), severe stroke (adjusted OR: 1.38, 95% CI: 1.06–1.83, p = 0.018), and PFO at 3 months (adjusted OR: 1.16, 95% CI: 1.04–1.30, p = 0.008). ROC analysis identified IMA cutoffs of >58 ng/mL for AIS (AUC: 0.859), >76.7 ng/mL for severe stroke (AUC: 0.890), and >65.4 ng/mL for PFO (AUC: 0.854). Conclusion: Serum IMA levels are elevated in AIS and correlate with both initial stroke severity and short-term functional outcomes. IMA may serve as a rapid, cost-effective biomarker for early risk stratification in AIS.

15 October 2019 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
MOMerve Sena Odabasi
Merve Sena Odabasi
MDMelahat Dirican
Melahat Dirican
AOArzu Yilmaztepe Oral
Arzu Yilmaztepe Oral
GOGuven Ozkaya
Guven Ozkaya
Background: It is responsibility of medical laboratories to determine and reject nonconforming samples as well as take preventive actions. In this study, we examined reasons and percentages of rejected samples. We also investigated impact of the preventive actions on decreasing the rejection rates. Materials and methods: Reasons for rejection were determined by Pareto analysis. Sigma analysis was used for each month to evaluate the ratios and compare with other studies. Some preventive actions were taken to reduce the rejection rates. Pearson’s chi square test was used to evaluate effects of preventive actions. Significance level was determined as p < 0.05. Results: Most of the rejected samples consisted of samples not received by the laboratory, haemolysed and insufficient samples. The percentages of samples not received by the laboratory and insufficient samples were reduced from 3.80% to 1.94% and 0.33% to 0.31% respectively, while haemolysed samples percentage was increased from 2.83% to 3.37% after the improvement actions. Also, sigma levels for samples not received by the laboratory and haemolysed samples were at the minimum while insufficient samples were at a reasonable level. Conclusion: Improvement actions achieved statistically significant decreases for samples not received by the laboratories for a long-term.

20 April 2025 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
MKMert Karaca
Mert Karaca
GAGözde Arslan
Gözde Arslan
DEDiğdem YÖYEN ERMİŞ
Diğdem YÖYEN ERMİŞ
Salih Haldun BalSalih Haldun Bal
Salih Haldun Bal
EUEsra Kunt Uzaslan
Esra Kunt Uzaslan
HOHaluk Barbaros Oral
Haluk Barbaros Oral
Kinürenin yolağı, yol boyunca oluşan metabolitler ve enzimler aracılığıyla neredeyse tüm bağışıklık tepkileriyle etkileşime girmektedir. Hız sınırlayıcı enzim olan indolamin 2,3-dioksijenaz (IDO), yolağın başlangıç adımında oksidoredüktaz olarak görev yapmakta olup triptofanın kinürenine dönüşümünü katalizler ve çeşitli enfeksiyöz hastalıkların patogeneziyle ilişkilendirilmiştir. Bu çalışmada, koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] hastalarının serum IDO-1 düzeyleri, Th1-2- 17 ile ilişkili sitokinlerin düzeyleri ve hematolojik parametreler, hastalığın şiddeti (hafif, orta, şiddetli) göz önünde bulundurularak araştırılması amaçlanmıştır. Yüz otuz hasta ve 91 sağlıklı kontrol için IDO1 serum seviyeleri enzim ilişkili immünsorban assay [enzyme linked immunosorbant assay (ELISA)] yöntemi kullanılarak ölçülmüş ve karşılaştırılmıştır. IDO gen lokusundaki daha önce enflamasyonla ilişkilendirilmiş olan tek nükleotit polimorfizm [single nucleotid polymorphism (SNP)] bölgesi taranmıştır. SNP analizleri, erime eğrisi (melting curve) analiziyle gerçekleştirilmiştir. Kırk COVID-19 hastasının IDO-1 intronik varyant rs7820268 ve IDO-2 inaktivitesinden sorumlu rs4503083 SNP bölgeleri, elli iki sağlıklı kontrol ile karşılaştırmalı olarak incelenmiştir. Tüm sonuçlar istatistiksel olarak analiz edilmiş ve karşılaştırılmıştır. IDO-1 serum konsantrasyonları hasta grubunda sağlıklı kontrol grubuna göre anlamlı olarak düşük bulunmuştur (p< 0.0001). Ayrıca, şiddetli hasta grubundaki IDO-1 serum seviyeleri, hafif hasta grubundan daha düşük olarak belirlenmiştir (p= 0.026). Hasta grubunda IL-4, IL-6, IL-10, TNF-α serum seviyeleri anlamlı derecede yüksek bulunurken, IFN-γ seviyeleri düşük olarak tespit edilmiştir. IDO1 ve IL-6 seviyeleri arasında ise negatif bir korelasyon bulunmuştur (r= -0.3503, p= 0.0391). Hastalık şiddetine göre sınıflandırılan hasta gruplarında lenfosit, monosit, nötrofil ve akut faz reaktan değerleri karşılaştırıldığında anlamlı farklılıklar bulunmuştur. SNP analizi sonucunda, rs7820268 IDO-1 bölgesi için CC genotipi COVID-19 hasta grubunda sağlıklı kontrol grubuna göre önemli ölçüde daha yüksek bulunmuştur (p= 0.0017). Bu veriler, IDO-1 rs7820268 SNP bölgesindeki polimorfizmin COVID-19'a duyarlılıkla ilişkili olabileceğini düşündürmektedir.